Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, DoubleBlind Phase 2 Trial | |
Cheng, Y.; Wang, Q.; Li, K.; Shi, J.; Wu, L.; Han, B.; Chen, G.; He, J.; Wang, J.; Qin, H. | |
2018 | |
卷号 | 13期号:10页码:S351-S352 |
关键词 | Anlotinib 3rd line relapsed SCLC |
ISSN号 | 1556-0864 |
DOI | 10.1016/j.jtho.2018.08.308 |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6350413 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Cheng, Y.,Wang, Q.,Li, K.,et al. Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, DoubleBlind Phase 2 Trial[J],2018,13(10):S351-S352. |
APA | Cheng, Y..,Wang, Q..,Li, K..,Shi, J..,Wu, L..,...&Li, X..(2018).Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, DoubleBlind Phase 2 Trial.,13(10),S351-S352. |
MLA | Cheng, Y.,et al."Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, DoubleBlind Phase 2 Trial".13.10(2018):S351-S352. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论